

# Axinn Obtains Denial of a TRO Motion for Client Zydus

NEWS | LESS THAN 1 MIN READ

April 23, 2015

Axinn attorneys succeeded in obtaining a denial of a TRO motion that had sought an order to keep Axinn client Zydus from marketing its generic version of Abilify (aripiprazole). Abilify is a multi-billion dollar drug marketed by Otsuka, and Otsuka sought a ruling from the United States District Court for the District of New Jersey that the marketing of Zydus' generic aripiprazole product would infringe Otsuka's patent. The Axinn team included Jason Murata. Additionally, the firm was joined by a number of other defendants in opposing Otsuka's TRO motion.

## Related People

---



Jason Murata

## Related Services

---

To subscribe to our publications, [click here](#).

## Featured Insights

- GCR Live: Law Leaders Europe 2025  
**SPEAKING ENGAGEMENT     ANTITRUST**
- AHLA Annual Meeting 2025  
**SPEAKING ENGAGEMENT     ANTITRUST**
- SABA North America Annual Conference 2025  
**SPEAKING ENGAGEMENT     ANTITRUST**
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses  
**WEBINAR     ANTITRUST**
- Volunteer Lawyers for the Arts – Champions of the Arts Awards and Gala 2025  
**SPONSORSHIP     ANTITRUST**
- NJSBA Annual Meeting and Convention 2025  
**SPEAKING ENGAGEMENT     INTELLECTUAL PROPERTY**
- Cost-Effective and Efficient IP Litigation Strategies – Making Paragraph IV Litigation Work for You  
**WEBINAR     INTELLECTUAL PROPERTY**
- Hartford HealthCare Black and Red Gala 2025  
**SPONSORSHIP     ANTITRUST**
- Informa CompLaw Antitrust West Coast Conference 2025  
**SPEAKING ENGAGEMENT     ANTITRUST**
- Recent Decision Shows the Heavy Burden of Actual Malice in Defamation Suits  
**AXINN VIEWPOINTS     LITIGATION & TRIALS**

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved